Document:

Exhibit 10.43

 

 PORTIONS
OF THIS AGREEMENT WERE OMITTED AND HAVE BEEN FILED

SEPARATELY
WITH THE SECRETARY OF THE COMISSION PURSUANT TO AN

APPLICATION
FOR CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE

SECURITIES
EXCHANGE ACT OF 1934; [***] DENOTES OMISSIONS

 

THIRD
AMENDMENT TO EXCLUSIVE DISTRIBUTION AND LICENSING AGREEMENT

 

This
Third Amendment (the “Third Amendment”) is entered into on December 26, 2017 (the “Effective Date”),
by and between Resdevco Research and Development Company Ltd., reg. no. 510422223 (the “Licensor”) and Wize
Pharma Ltd., reg. no. 520033259, the former name of which is Star Night Technologies Ltd. (the “Licensee”)
(the Licensor and the Licensee shall be collectively referred to hereinafter as the “Parties”).

 

WHEREAS,
the Licensor and the Licensee have entered into that certain Exclusive Distribution and Licensing Agreement dated May 1, 2015
(the “License Agreement”), setting forth the terms and conditions of the license and distributor’s rights
granted by the Licensor to the Licensee solely in the territory of the United States of America; and

 

WHEREAS,
the Licensor and the Licensee have expanded the scope of the License Agreement to additional territories by executing an two amendments
to the License Agreement: (i) an amendment expanding the License Agreement to the territory of the State of Israel; and (ii) an
amendment expanding the License Agreement to the territory of Ukraine (collectively the “Previous Amendments”);
and

 

WHEREAS,
the Licensee has signed a Framework Agreement with a leading Chinese pharmaceutical wholesale corporation (“Distributor”),
in the territory of the People’s Republic of China (the “Prospected Chinese Sub-Distribution Agreement”
and “China”, respectively); and

 

WHEREAS,
the Licensor and the Licensee wish to apply the terms of the License Agreement to the territory of China, conditioned on the execution
of Prospected Chinese Sub-Distribution Agreement, as further provided in this Third Amendment

 

NOW
THEREFORE, the Parties hereby declare and agree as follows:

 

		1.	Capitalized
                                         terms used but not otherwise defined herein shall have the meaning ascribed to them in
                                         the License Agreement.

 

		2.	This
                                         Third Amendment is expressly conditioned on the execution of Prospected Chinese Sub-Distribution
                                         Agreement. In the event Prospected Chinese Sub-Distribution Agreement has not been duly
                                         executed by all parties thereto by June 1, 2018, this Third Amendment shall be deemed
                                         null, void and of no force.

 

		3.	The
                                         following terms are agreed between the Parties, and shall accordingly amend the License
                                         Agreement:

 

		a.	The
                                         term of 7 years specified in Articles 11.2 of the License Agreement shall be changed
                                         to 60 months automatically renewed for additional 12-month periods (only in regards to
                                         this Third Amendment) based on Licensee’s fulfillment of obligations set forth
                                         herein (the “Term”). The aforesaid amended shall apply to all references
                                         to the Term of the Agreement (including to “minimum duration” or such other
                                         references in the Agreement) mutatis mutandis.

 

		b.	The
                                         Licensee’s rights and obligations under the License Agreement shall be expanded
                                         to the territory of China, so that the term “Territory” shall be amended
                                         as set forth below in Section 5(a) of this Third Amendment, and the provisions of the
                                         License Agreement shall apply to the Territory (as amended hereby, including China) mutatis
                                         mutandis.

 

    

     

    

 

		c.	The
                                         Common Technical Document (CTD) submitted to DISTRIBUTOR is the property of the Licensor
                                         and Licensor grants Licensee the right to freely use the CTD for the purposes of executing
                                         and carrying out the Prospected Chinese Sub-Distribution Agreement.

 

		d.	Licensee
                                         will ensure that the Prospected Chinese Sub-Distribution Agreement obligates Distributor
                                         to transfer the Chinese Market License, obtained by Distributor to the Licensor so that
                                         the Chinese Market License will become the property of the Licensor, upon termination
                                         of the Prospected Chinese Sub-Distribution Agreement.

 

		4.	As
                                         of the Effective Date and throughout the Term the following sections of the License Agreement
                                         shall be amended as follows:

 

		a)	Under
                                         the heading “Definitions” in the preamble of the License Agreement
                                         the definition of “Territory” shall be replaced in its entirety by the following
                                         language:

 

“Territory”
shall mean the United States of America and the People’s Republic of China.”

 

		b)	Throughout
                                         the entire License Agreement the term “FDA” should shall be replaced
                                         by the following language:

 

“FDA
(US Food and Drug Administration) and/or CFDA (China Food and Drugs Administration), as applicable”

 

		c)	At
                                         the end of Article 7.1 in the License Agreement the following language shall
                                         be added:

 

“Solely
with respect to the territory of China (and for avoidance of any doubt - without derogating from the Licensee’s obligations
to make full payments under this Article 7 with regard to the USA) the following shall apply:

 

		1.	The
                                         royalty payment per Unit/Box and yearly minimum royalty payment obligations, as described
                                         in this Article 7, shall commence on the earlier of January 1 of the year following the
                                         year in which any type of marketing approval is obtained for the Finished Product in
                                         China (the “China Royalties Commencement Date”);

 

		2.	“Unit/Box”
                                         shall mean a package of 30 unit-dose eye drops (namely 30 single-dose containers of eye
                                         drops, hereinafter the “Unit-Dose Eye Drops”) described in Appendix A. 

 

		3.	During
                                         the first [***] years starting from the China Royalties Commencement Date (the “Grace
                                         Period”), the Licensee shall pay the Licensor a reduced royalty payment of
                                         $[***] per each Unit/Box of the Finished Product and/or any other product making use
                                         of the Licensed Technology actually sold in China (and for which payment is actually
                                         received by Licensee) (the “Reduced Royalty Payment”). Following the
                                         Grace Period the Licensee shall pay the Licensor a regular royalty payment of $[***]
                                         per each Unit/Box of the Finished Product and/or any other product making use of the
                                         Licensed Technology actually sold in China (and for which payment is actually received
                                         by Licensee).

 

		4.	For
                                         any sales in the Territory prior to the China Royalties Commencement Date the Licensee
                                         shall pay the Licensor a regular royalty payment of $[***] per each Unit/Box of the Finished
                                         Product, 

 

    	 	2	 

     

    

 

		5.	Following
                                         the Grace Period, the Licensor shall participate in the cost of reasonable and customary
                                         financial instrument that will be purchased by the Licensee in order to protect its’
                                         distribution activity in China from fluctuations in rates of foreign currencies (the
                                         “Insurance Cost”). The Licensor’s share in the Insurance Cost
                                         shall be to the Insurance Cost covering the fluctuation of $[***] per each Unit/Box of
                                         the Finished Product. The aforesaid Licensor’s share shall be paid by the Licensor
                                         against a proper invoice from the Licensee, and in no event shall be deemed as independent
                                         obligation of the Licensor towards the Licensee. The Licensee shall send to the Licensor
                                         documents evidencing the Insurance Cost. 

 

		6.	The
                                         minimum yearly royalty payments as described in this Section 7 with respect to sales
                                         in China only shall be as follows:

 

	 	Year	Unit-Dose
    	Royalty
    in $	Reduced
Royalty in $

	 	[***]
    month as of the Commencement Date	[***]	[***]	[***]
	 	[***]
    month as of the Commencement Date	[***]	[***]	[***]
	 	[***]
    month as of the Commencement Date	[***]	[***]	  [***]*
	 	[***]
    month as of the Commencement Date	[***]	[***]	  [***]*
	 	[***]
    month as of the Commencement Date and later	[***]	[***]	  [***]*

 

	 	*	These numbers are relevant solely for the purpose of
sub-section (7) below.

 

		7.	In
                                         case after the Grace Period a calculation of a certain year’s royalty payment shall
                                         exceed an amount equal to [***] times the applicable minimum yearly royalty payment stated
                                         in Section (6) above (the “[***] Reduced Payment”), then for that
                                         specific year the Licensee shall pay the Licensor the Reduced Royalty Payment for any
                                         sales that exceed the [***] Reduced Payment

 

    	 	3	 

     

    

 

		8.	Without
                                         derogating from Licensee’s obligation to complete until the end of each calendar
                                         year the full payment of the minimum royalty payments as described in sub-section (6)
                                         above, the Licensee shall pay royalty payments as described in Article 7 of the License
                                         Agreement within 14 (fourteen) days following an actual payment received by the Licensee
                                         from its clients of sub-distributors (including Distributor The burden of proof with
                                         respect to any non-payment to the Licensee is expressly imposed on the Licensee

 

		9.	The
                                         minimum duration for termination, as described and defined in Sec. 11.1 below, shall
                                         be five (5) years commencing from the Commencement Date All other provisions of Article
                                         11 shall apply to the territory of China mutatis mutandis. 

 

		d)	At
                                         the end of Articles 7.1 the following language shall be added:

 

“Solely
with respect to the territory of the USA:” 

 

		e)	At
                                         the beginning of Article 12.3 the following language shall be added:

 

“Solely
with respect to the territory of the USA:”

 

		f)	At
                                         the end of Article 15.1 the following language shall be added:

 

“Solely
with respect to the territory of China and notwithstanding anything to the contrary in this Agreement, the Finished Product
shall be marked under the trademark ’Lacrycon®’” or any other brand approved by Licensor.

 

		5.	Sections
                                         5 and 6 of Appendix A to the License Agreement as well as Appendices B and C in their
                                         entirety shall not apply to the territory of China.

 

		6.	Notwithstanding
                                         anything to the contrary in the License Agreement, the rights granted to the Licensee
                                         with respect to the territory of China shall apply only to the Product Any deviation
                                         therefrom as well as any change in the line of R&D or marketing activity of the Licensee
                                         in connection with the Chinese market requires prior written consent of the Licensor.
                                         Without derogating from the generality of the foregoing and of the applying of the License
                                         Agreement on the territory of China, and for the avoidance of any doubt, the Licensee
                                         may not engage with any manufacturer other that PharmaStulln Germany without prior written
                                         consent of the Licensor.

 

		7.	Except
                                         as explicitly provided above, this Third Amendment shall not derogate from or amend the
                                         provisions of the License Agreement or the Previous Amendments, and they shall remain
                                         in full force and effect throughout their terms.

 

		8.	The
                                         Prospected Chinese Sub-Distribution Agreement shall include provisions according to which
                                         Distributor consents that immediately upon the occurrence of any of the events described
                                         in Article 12.1 of the License Agreement, any and all rights of the Licensee under the
                                         Prospected Chinese Sub-Distribution Agreement shall be transferred, or assigned, subject
                                         however to the Licensor’s prior written consent to the Licensor. In any case, Licensor
                                         will ensure that the manufacturing authorization license to PharmaStulln will continue.

 

		9.	For
                                         the avoidance of doubt, the Licensor expressly disclaims any direct liability towards
                                         any third party, including Distributor, in connection with the Prospected Chinese Sub-Distribution
                                         Agreement.

 

		10.	Except
                                         for the termination in accordance with Article 12.1 to the License Agreement, termination
                                         of the License Agreement with respect to the territory of the USA will not result in
                                         termination of the terms of License Agreement with respect to China.

 

    	 	4	 

     

    

 

		11.	Miscellaneous.

 

		a)	The
                                         License Agreement, the Previous Amendments and this Third Amendment constitutes the entire
                                         understanding and agreement between the Parties with regard to the subject matter hereof
                                         and supersedes any and all prior discussions, agreements and correspondence with regard
                                         to the subject matter hereof. In the event of any inconsistency between the provisions
                                         of this Third Amendment and the provisions of the License Agreement and Previous Amendments,
                                         the provisions of this Third Amendment shall prevail.

 

		b)	Any
                                         term of this Third Amendment may be amended and the observance of any term of this Third
                                         Amendment may be waived (either generally or in a particular instance and either retroactively
                                         or prospectively), only with the written consent executed by the Parties.

  

IN
WITNESS WHEREOF, the Parties have entered into this Third Amendment as of the date written above.

 

	Resdevco Research and Development Company Ltd.	 	Wize Pharma Ltd.
	 	 	 	 	 
	By:	/s/ Professor S. Dikstein	 	By:	/s/ Or Eisenberg
	Title:	CEO

	 	Title:	CFO and Acting CEO

 

 

5Exhibit 10.44

 

PORTIONS
OF THIS AGREEMENT WERE OMITTED AND HAVE BEEN FILED

SEPARATELY
WITH THE SECRETARY OF THE COMISSION PURSUANT TO AN

APPLICATION
FOR CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE

SECURITIES
EXCHANGE ACT OF 1934; [***] DENOTES OMISSIONS

 

Memorandum
Of Understandings

 

This
memorandum of understanding (this “MOU”) is entered this January 8, 2018 and is intended to reflect our mutual
agreement concerning the contemplated assignment of distribution rights and a license from Resdevco Research and Development Ltd.
(Private Company 510422223, hereinafter “Resdevco”) to Wize Pharma Ltd. of Hanagr 5b Hod Hasharon, Israel (“Wize”).

 

In
this document the following terms will have the meaning corresponding to them as follows:

 

“Product”
shall mean Resdevco’s LO2A unit dose Eye Drops and all indications relating thereto, as described in Appendix C of the Agreement.

 

“Current
Territories” shall mean Switzerland, Germany, Holland, Israel, Ukraine and the USA.

 

“Additional
Territories” shall mean all territories other than Current Territories, excluding the People’s Republic of China

 

“Net
Sales” shall mean the income actually received by Wize from sales of the Product from the first fully independent market
organization in a sales chain to consumers, less commissions paid (by Wize) to third parties in connection with the production
and sale of the Product.

 

The
business understandings which we have reached are as follows:

 

		1.	Worldwide
                                         License 

 

		1.1	The
                                         existing license agreement between the parties, including without limitation that certain
                                         Exclusive Distribution and Licensing Agreement dated May 1, 2015 between the parties
                                         attached hereto as Appendix A (the “License Agreement”) shall continue to
                                         be in full force and effect, and its continuing effect shall be a condition precedent
                                         to the effect of the undertakings in this MOU, and to the continuing effect of all agreements
                                         entered thereunder.

 

		1.2	Resdevco
                                         will grant Wize an exclusive license to sell and distribute the Product in Additional
                                         Territories - in return for royalties as set forth in Appendix B enclosed hereto for
                                         the Term of this Agreement. The license set forth herein shall not cover Current Territories
                                         (“License”).

 

    	 	1	 

     

    

 

		1.3	The
                                         License granted to Wize shall be conditioned, in each Additional Territory, on reaching
                                         minimum sales targets within the time frame stipulated for each such Additional Territory,
                                         in a specific license agreement which will need to be signed per each new Additional
                                         Territory, based on the general terms and conditions set forth herein, and as setforth
                                         in Appendix B enclosed hereto.

 

		1.4	In
                                         every Additional Territory in which the Products shall be sold - Resdevco shall be entitled
                                         to a minimum per Product as per the formula detailed in APPENDIX B, payable jointly and
                                         severally from Wize and the distributor appointed by it, and the agreement with each
                                         distributor, agent, or reseller of whatever form or structure, in each Additional Territory
                                         - shall require Resdevco’s prior written approval for above said territory. Subject to
                                         compliance with obligations stipulated in Appendix B, Resdevco’s prior written
                                         approval shall not be unreasonably withheld.

 

		1.5	The
                                         License hereunder will be granted for 5 years, and shall be automatically renewed for
                                         each additional term of 5 years, subject to full compliance with the terms herein, and
                                         the continuing effect of the License Agreement.

 

		1.6	[***]

 

		1.7	[***]

 

		1.8	Regardless
                                         of the party that initiated or finalized the deal with the distributor, Wize will be
                                         responsible for overseeing the registration process and enabling the relationship between
                                         the distributor and the Manufacturer in a timely manner and Wize shall use best efforts
                                         to enable the distribution of the Product

 

[***]

 

The
existing engagements of distributors in Current Territories shall continue to be in place, and shall continue to be managed by
Resdevco. The Parties will act to maintain business continuity in the Current Territories.

 

The
License Agreement shall be assigned to Wize Pharma Ltd, and shall inure to the benefit of the parties hereof. The distribution
agreement between the parties for Israel, Ukraine and China shall remain in place.

 

Wize
may assign this agreement to a third party providing Resdevco a written prior written notice and guaranteeing the compliance of
such assignee with the terms thereof. Such assignment shall require the prior written consent of Resdevco given in good faith,
and not to be unreasonably withheld.

 

    	 	2	 

     

    

 

		2.	Additional
                                         Terms and Conditions

 

The
term of this MOU is in effect until a definitive agreement is signed in respect of the subject matter hereof. The parties are
committed and will do their utmost effort to complete such a definitive agreement within three months.

 

If
Wize becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, files or has
filed against it a petition which is not reversed within 60 days of filing thereof, or institution of voluntary proceedings in
bankruptcy, liquidation, dismantling – all its rights under this MOU and all agreements entered subject thereto shall terminate
and be of no force and effect.

 

Resdevco
may freely assign and transfer its rights under this agreement or any of the agreements related therein to third parties.

 

Neither
Party hereto shall be liable for non-fulfillment of its obligations or for any failure or delay caused by force majeure, provided
such force majeure occurrence shall immediately be notified to the other party. So far as reasonable the activities held up by
force majeure shall be taken up as soon as adequately possible after the respective cause no longer prevails. In the event of
any delay resulting from such causes, the time for performance under this Agreement shall be extended on a day to day basis.

 

Except
as required by applicable law, none of the parties hereto (nor any of their respective affiliates, officers, directors, associates,
shareholders, advisors, agents or representatives) shall issue any press release or make any other public disclosure relating
to, or connected with, this letter or the matters contained herein (including, without limitation, the fact that this letter has
been executed or that the negotiations contemplated hereby have commenced) without obtaining the prior approval of the other party,
except for the disclosure by each of the parties hereto of this letter to its officers, directors and advisors on a need-to-know
basis provided such parties keep this letter and its content confidential, or as may be required under law, including without
limitation any regulated reporting requirements of Wize. Each party hereto agrees to maintain the confidentiality of this MOU
and the transactions contemplated hereby. This provision shall be binding on the parties, whether definitive agreements are entered
or not.

 

    	 	3	 

     

    

 

This
MOU shall be governed by, and construed in accordance with, the laws of the State of Israel, and without regard to its conflict
of law provisions. The place

of
any legal proceedings is Jerusalem, Israel

 

Any
legal action or proceeding with respect to any of the obligations arising under or relating to this MOU will be brought to the
competent courts in Jerusalem which shall have an exclusive jurisdiction in respect thereof.

 

No
reliance may be made on the agreement reflected herein by any person, including the parties hereof, and no liability or rescission
or change in the terms hereof shall be assumed by either party.

 

Confirmed
and agreed as of the date first set forth above.

 

	 	Wize Pharma Ltd.	 	Resdevco Ltd.
	 	 	 	 	 	 
	 	By	/s/
Or Eisenberg	 	By	/s/ Prof. S. Dikstein
	 	 	Name:
    Or Eisenberg	 	 	Name:
    Prof. S. Dikstein
	 	 	Title:
    CFO & Acting CEO	 	 	Title:
    CEO

 

    	 	4	 

     

    

 

Appendix
A

 

Commitments
by Wize Pharma

 

Wize
is committed to completing two double-blind clinical trials, according to a Protocol prepared under the supervision of Wize and
applicable Ethics Committee (IRB) Approvals and other regulatory approvals, as may be required. The duration of the clinical trial
will be dependent on the number of participants recruited. Wize shall extend best efforts to recruit the required number of patients
in the designated timeframe, but if recruitment is low, the parties will extend the time frame for completion of the clinical
trials accordingly.

 

The
first will test the efficacy of the Product for treating Conjunctivochalasis

 

The
Second will test the efficacy of the Product for treating Sjogren’s Syndrome Dry Eyes

 

Both
the above clinical trials should be completed by [***].

 

Wize
is committed to complete the Pre-IND process vis a vis the FDA for the the indications: “treating Conjunctivochalasis”
and/or the indication “treating Sjogren’s Syndrome Dry Eyes”, as per regulatory specialist recommendations,
and receive the said recommendations and plan by [***]

 

    	 	5	 

     

    

 

Appendix
B

 

The
royalties for sales in Additional Territories and in the USA will be the higher of $[***] or [***]% from Net Sales for the duration
of the local distribution agreement signed separately with each local distributor.

  

Minimum
annual sales target formula is [***].

 

If
it is less than $[***] per year, then the minimum sales target is prorated by the GDP.

 

[***]

 

    	 	6	 

     

    

 

Appendix
C

 

PRODUCT
description and formula

 

1.
Unit dose or any other future dose or packaging eye drops to treat dry eye and/or Conjunctivochalasis currently sold in Hungary
as Conheal® (in Germany as Hylan®) The product is currently manufactured by PharmaStulln GmbH in Germany and by Excel
Vision in France currently sold in Switzerland as Lacrycon®. In the future, the Product may be produced by another contract
manufacturer approved by Resdevco.

 

3.
The expenses involving the box design for the Territory are paid by LICENSEE.

 

4.
As far as RESDEVCO knows the ex factory= ex works price of Conheal® (containing 2x5x3 =30 unit dose) is [***] euro.

 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]